Salil Khandwala, MD
Urogynecology and Reconstructive Pelvic Surgery · Dearborn, MINPI 1932178936
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (46.0%), food and beverage and education — rather than concentrated in one kind of arrangement. Coloplast accounts for 70.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $3,473 and has fallen 98.7% since, to $46 in 2025.
Across 59 payments — averaging $113.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$5K
- Axonics, Inc.$1K
- LINA Medical USA Inc$497
- Astellas Pharma US Inc$80
- AbbVie$51
- Johnson & Johnson$38
- plus $66 from 3 others
Across 62 payments — averaging $6777.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$310K
- Boston Scientific$110K
What the payments were for
- Travel & lodging$3,09146%
- Food & beverage$2,05431%
- Education$1,58023%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 43 | $4,722 |
| Axonics, Inc. | 7 | $1,270 |
| LINA Medical USA Inc | 1 | $497 |
| Astellas Pharma US Inc | 1 | $80 |
| AbbVie(2 entities) | 3 | $51 |
| Johnson & Johnson | 1 | $38 |
| Medtronic | 1 | $33 |
| Femselect Inc. | 1 | $18 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,724 in reported general payments places this provider in the 75th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
See all urogynecology and reconstructive pelvic surgery providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 129 | $89,794 |
| GemtesaVibegron | 92 | $76,724 |
| Mirabegron ErMirabegron | 55 | $32,320 |
| Methenamine Hippurate | 137 | $14,155 |
| Trospium Chloride ErTrospium Chloride | 48 | $11,323 |
| PremarinEstrogens, Conjugated | 18 | $7,752 |
| Fosfomycin Tromethamine | 24 | $3,691 |
| Solifenacin Succinate | 73 | $2,148 |
| Estradiol | 25 | $2,011 |
| NitrofurantoinNitrofurantoin Macrocrystal | 42 | $1,701 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 179 | $1,319 |
| Gabapentin | 51 | $981 |
| Tamsulosin Hcl | 39 | $800 |
| Amitriptyline Hcl | 77 | $696 |
| Cephalexin | 34 | $405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $80 | $89,794129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
Other urogynecology and reconstructive pelvic surgery in Dearborn
- Jason CruffDearborn$12K
- Jannah ThompsonNorton Shores$474K
- Jason BennettGrand Rapids$68K
- Priyanka GuptaAnn Arbor$39K
- John DelanceyAnn Arbor$11K
- Melissa FischerRoyal Oak$11K
- Anne CameronBrighton$7K
- Ali LuckWest Bloomfield$7K
- Gabrielle RohrerRoyal Oak$5K
- Hope BauerGrand Rapids$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.